Speech apraxia
Gene: EBF3
First reported CAS case with a de novo EBF3 nonsense variant (Hildebrand et al., 2020; PMID: 32345733).
Chao et al. (2017; PMID: 28017372) report three independent cases with de novo missense variants (all three curiously substituting the same amino acid). All three cases had "expressive speech disorder (3/3)" and one was reported with apraxia.
Deisseroth et al. (2022; PMID: 35340043) report a total of 83 individuals with missense or protein-truncating variants for EBF3 from a meta-analysis and find 10% have speech apraxia. Specifically, of these ten cases, carried de novo EBF3 variants and were reported as having speech apraxia (supplementary tables).
Sources: Expert list, Expert ReviewCreated: 25 Jun 2024, 6:30 a.m. | Last Modified: 1 Jul 2024, 10:28 a.m.
Panel Version: 0.38
Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Phenotypes
Hypotonia, ataxia, and delayed development syndrome, MIM# 617330
Publications
Gene: ebf3 has been classified as Green List (High Evidence).
Gene: ebf3 has been classified as Green List (High Evidence).
gene: EBF3 was added gene: EBF3 was added to Speech apraxia. Sources: Expert list,Expert Review Mode of inheritance for gene: EBF3 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted Publications for gene: EBF3 were set to 32345733; 28017372 Phenotypes for gene: EBF3 were set to Hypotonia, ataxia, and delayed development syndrome, MIM# 617330 Review for gene: EBF3 was set to GREEN